A vaccine developed by US-based Pfizer and Germany's BioNTech has shown 90% efficacy in trials, but pharma giant says the number may vary with further trials.
Berlin gave the German company $445 million in an agreement in September to help accelerate the vaccine by building out manufacturing & development capacity in its home market.
Pfizer and BioNTech announced Monday that their vaccine candidate prevented over 90% of Covid-19 cases in an early look at results from their 44,000-person clinical trial.
With effectiveness for first vaccines previously expected to be in range of 60% to 70%, more than 90% for Pfizer’s Covid vaccine is seen as extraordinary.
Pfizer and BioNTech on track to potentially be the first to show the efficacy of a Covid-19 vaccine, in an environment of intense scrutiny over every possible complication.
A little patience would help deliver much more information and give other vaccine hopefuls, apart from the front-runners, a chance to prove their worth as well.
Pfizer chief Albert Bourla says his firm and its partner BioNTech have a 60% chance of knowing the efficacy of their still experimental vaccine by end of October.
Countering insurgency needs the Pakistan Army to demonstrate a political will that ties leaders at the centre with those in the borderlands. But it may not have the imagination.
Centre for Science and Environment in new report makes case for rationalising GST on waste material, saying most informal operators can’t afford high tax & it also hinders recycling.
21st edition of annual joint military exercise will be held from 1 to 16 September, aimed at sharing military tech, operational best practices & disaster relief coordination methods.
Standing up to America is usually not a personal risk for a leader in India. Any suggestions of foreign pressure unites India behind who they see as leading them in that fight.
COMMENTS